We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

24 hedge funds and large institutions have $2.5M invested in Lisata Therapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more capital invested

Capital invested by funds: $1.11M → $2.5M (+$1.4M)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0.08% more ownership

Funds ownership: 0.32% → 0.4% (+0.08%)

20% less funds holding

Funds holding: 30 → 24 (-6)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
24
Holders Change
-6
Holders Change %
-20%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$288K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$197K
3
BlackRock
BlackRock
New York
+$123K
4
Renaissance Technologies
Renaissance Technologies
New York
+$115K
5
VKH
Virtu KCG Holdings
New York
+$71.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$45K
2
Goldman Sachs
Goldman Sachs
New York
-$31K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$31K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$13.4K
5
Morgan Stanley
Morgan Stanley
New York
-$8.38K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$761K +$197K +2,843 +39%
KCM
2
Knoll Capital Management
Florida
$593K +$288K +4,159 +112%
Renaissance Technologies
3
Renaissance Technologies
New York
$491K +$115K +1,660 +34%
VKH
4
Virtu KCG Holdings
New York
$183K +$71.6K +1,033 +75%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$148K +$208 +3 +0.2%
BlackRock
6
BlackRock
New York
$134K +$123K +1,779 New
Jacobs Levy Equity Management
7
Jacobs Levy Equity Management
New Jersey
$91K -$13.4K -193 -14%
PAM
8
Panagora Asset Management
Massachusetts
$36K – – –
Morgan Stanley
9
Morgan Stanley
New York
$18K -$8.38K -121 -34%
UBS Group
10
UBS Group
Switzerland
$17K +$624 +9 +4%
Wells Fargo
11
Wells Fargo
California
$10K +$8.94K +129 +12,900%
Fifth Third Bancorp
12
Fifth Third Bancorp
Ohio
$5K – – –
Bank of America
13
Bank of America
North Carolina
$3K – – –
IA
14
IFP Advisors
Florida
$3K – – –
Northwestern Mutual Wealth Management
15
Northwestern Mutual Wealth Management
Wisconsin
$2K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$2K +$1.39K +20 New
LTFS
17
Ladenburg Thalmann Financial Services
Florida
$1K -$554 -8 -42%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$1K -$139 -2 -20%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$1K – – –
Citigroup
20
Citigroup
New York
$1K – – –
Citadel Advisors
21
Citadel Advisors
Florida
– -$45K -1,052 Closed
Goldman Sachs
22
Goldman Sachs
New York
– -$31K -741 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$31K -728 Closed
Group One Trading
24
Group One Trading
Illinois
– -$1K -12 Closed
Creative Planning
25
Creative Planning
Kansas
– -$139 -2 -40%
1
2

LSTA Hedge Fund Activity: Q1 2017 in Review

24 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2017, worth a combined $2.5M — up 126% from $1.11M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LSTA and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Knoll Capital Management, adding an estimated $288K. The largest seller was Citadel Advisors, exiting entirely with an estimated $45K sold.

  • 24 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2017, down from 30 in Q4 2016.
  • Funds reported $2.5M of Lisata Therapeutics stock for Q1 2017, up 126% quarter-over-quarter.
  • 2 funds opened new Lisata Therapeutics positions in Q1 2017 and 6 closed out, a net change of -4 holders.
  • The largest Lisata Therapeutics buyer in Q1 2017 was Knoll Capital Management, an estimated $288K added.
  • The largest Lisata Therapeutics seller in Q1 2017 was Citadel Advisors, an estimated $45K sold.

Based on aggregated 13F filings for Q1 2017.